Skip to content
sugarisadrug.com
  • Home
  • Diabetes
  • Health News
  • General Sugar
  • Food Choices
  • Insulin
  • Mental Health
  • Stop Eating Sugar
  • Stop Killing Yourself
  • Fructose
  • Sugar Science

Month: June 2026

1317-OR: Optimized Protocol for Rapid Functional β-Cell Generation from Human Pluripotent Stem Cells

June 10, 2026 by sugaradmin

Introduction and Objective: Despite recent improvements in generating functional human insulin-producing β cells, stem cell-derived beta-like cells (sBC) still develop and function less efficiently than bona fide β cells from cadaveric islets. Therefore, we sought to identify key factors affecting efficient sBC generation during differentiation, with a focus on reducing time for sBC generation while […]

Read More
DiabetesLeave a Comment on 1317-OR: Optimized Protocol for Rapid Functional β-Cell Generation from Human Pluripotent Stem Cells

1293-OR: Changes in Diabetic Retinopathy (DR) in People with Type 1 Diabetes Using Tirzepatide for >1 Year

June 10, 2026 by sugaradmin

Introduction and Objective: Use of dual glucagon-like-peptide-1/glucose-dependent insulinotropic polypeptide receptor-agonists is increasing in overweight/obese (OW/OB) individuals with T1D. Their effects on DR in individuals with T1D are unknown.Methods: Retrospective chart review of OW/OB individuals with T1D at the Barbara Davis Center for Diabetes. Individuals who used tirzepatide for 12 ± 2 months (cases) were matched […]

Read More
DiabetesLeave a Comment on 1293-OR: Changes in Diabetic Retinopathy (DR) in People with Type 1 Diabetes Using Tirzepatide for >1 Year

1289-OR: Effect of Different Treatment Durations of Sodium–Glucose Cotransporter 2 Inhibitor on Cardiovascular Outcomes in Patients with Type 2 Diabetes: A Target Trial Emulation Study

June 10, 2026 by sugaradmin

Introduction and Objective: Despite cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i), treatment persistence is suboptimal in routine clinical practice. We investigated whether longer treatment durations offer greater cardiovascular benefits.Methods: We used nationwide healthcare data of South Korea (2012-2023) to emulate a target trial comparing following treatment strategies: treated with SGLT2i for <1 year, 1-2 […]

Read More
DiabetesLeave a Comment on 1289-OR: Effect of Different Treatment Durations of Sodium–Glucose Cotransporter 2 Inhibitor on Cardiovascular Outcomes in Patients with Type 2 Diabetes: A Target Trial Emulation Study

1322-OR: Synergistic Effects of Dorzagliatin and Orforglipron on Glycemic Control and Adiposity in DIO Mice

June 10, 2026 by sugaradmin

Introduction and Objective: T2DM is often driven by obesity, which leads to impaired glucose homeostasis and β-cell dysfunction. While oral small-molecule GLP-1RAs, such as orforglipron, promote weight reduction, dose-dependent gastrointestinal adverse effects can limit adherence. Dorzagliatin, a first-in-class glucokinase activator, enhances glucose sensing and early-phase insulin secretion. We evaluated whether combining these two oral agents […]

Read More
DiabetesLeave a Comment on 1322-OR: Synergistic Effects of Dorzagliatin and Orforglipron on Glycemic Control and Adiposity in DIO Mice

1285-OR: HYPO-VR: Virtual Reality Training Program to Improve Peer Recognition and Response to Hypoglycemia on College Campuses

June 10, 2026 by sugaradmin

Introduction and Objective: Transitioning to college increases the risk for hypoglycemia due to irregular schedules, alcohol use, and unpredictable access to food or glucose, highlighting the need for campus-based training to improve hypoglycemia-related safety. This study evaluated the effectiveness of HYPO-VR for on-campus hypoglycemia education.Methods: We conducted a two-arm pilot educational trial with undergraduate students. […]

Read More
DiabetesLeave a Comment on 1285-OR: HYPO-VR: Virtual Reality Training Program to Improve Peer Recognition and Response to Hypoglycemia on College Campuses

1321-OR: Superior Quality of Weight Loss with a Novel Unimolecular Tetra-Agonist Peptide Targeting GLP-1, GIP, Amylin, and Calcitonin Receptors vs. Tirzepatide and Cagrisema in Diet-Induced Obese Rats

June 10, 2026 by sugaradmin

Introduction and Objective: The rising prevalence of obesity and related comorbidities highlights the need for safe, effective, and durable therapies. We evaluated PTT-A, a novel long-acting tetra-agonist targeting GLP-1, GIP, amylin, and calcitonin receptors, in diet-induced obese (DIO) rats and compared its efficacy with tirzepatide and CagriSema.Methods: DIO rats received PTT-A (10 or 30 nmol/kg), […]

Read More
DiabetesLeave a Comment on 1321-OR: Superior Quality of Weight Loss with a Novel Unimolecular Tetra-Agonist Peptide Targeting GLP-1, GIP, Amylin, and Calcitonin Receptors vs. Tirzepatide and Cagrisema in Diet-Induced Obese Rats

1282-OR: Major Adverse Limb Events with Tirzepatide vs. Injectable Semaglutide in Adults with Type 2 Diabetes and Peripheral Artery Disease

June 10, 2026 by sugaradmin

Introduction and Objective: Peripheral artery disease (PAD) increases the risk for amputations and limb-threatening events in people with type 2 diabetes (T2D). Tirzepatide and injectable semaglutide are associated with improved limb outcomes. However, real-world comparative outcomes are unknown.Methods: This retrospective cohort study used the TriNetX real-world global database across 112 healthcare organizations with over 130 […]

Read More
DiabetesLeave a Comment on 1282-OR: Major Adverse Limb Events with Tirzepatide vs. Injectable Semaglutide in Adults with Type 2 Diabetes and Peripheral Artery Disease

1301-OR: Mitraa-T2D: Comparative Real-World Outcomes of a Digital Conversational Support Tool on Engagement, Adherence, and Glycemic Control in Adults with Type 2 Diabetes

June 10, 2026 by sugaradmin

Introduction and Objective: Limited patient engagement and suboptimal adherence remain major barriers in type 2 diabetes management. Digital conversational support tools may reinforce self-care between clinic visits. This study aimed to determine whether use of a digital conversational support tool, as an adjunct to usual care, is associated with improved behavioral and glycemic outcomes compared […]

Read More
DiabetesLeave a Comment on 1301-OR: Mitraa-T2D: Comparative Real-World Outcomes of a Digital Conversational Support Tool on Engagement, Adherence, and Glycemic Control in Adults with Type 2 Diabetes

1305-OR: Emerging Type 1 Diabetes Screening and Intervention Programs: Insights from 63 Centers in the T1D Exchange Quality Improvement (Type 1 DiabetesX-QI) Collaborative

June 9, 2026 by sugaradmin

Introduction and Objective: Early stage T1D screening programs in routine clinical care are in their infancy. With the availability of teplizumab, a disease-modifying therapy that delays progression to Stage 3 T1D, there is an urgent need to reimagine T1D care. Understanding current screening practices can inform implementation strategies and identify gaps as the field moves […]

Read More
DiabetesLeave a Comment on 1305-OR: Emerging Type 1 Diabetes Screening and Intervention Programs: Insights from 63 Centers in the T1D Exchange Quality Improvement (Type 1 DiabetesX-QI) Collaborative

1330-OR: Quantifying the Kinetics of Proglucagon-Derived Peptide Fragments Using Somatostatin and Glucagon Infusion

June 9, 2026 by sugaradmin

Introduction and Objective: Prohormone convertase enzymes within α-cells process proglucagon into several peptides. These include glicentin (GLY), major proglucagon fragment (MPGF), and oxyntomodulin (OXM). Assessing their in vivo secretion (SR) can provide insights on α-cell function in health and disease. However, estimating their SR from peripheral concentrations requires knowledge of their kinetics. Here we propose […]

Read More
DiabetesLeave a Comment on 1330-OR: Quantifying the Kinetics of Proglucagon-Derived Peptide Fragments Using Somatostatin and Glucagon Infusion

Posts navigation

Older posts
Newer posts

Recent Posts

  • Sex-Dependent Diabetes Impact of Acute Grp78 Deletion in β-Cells of Adult Mice
  • Activating Transcription Factor 6α Governs Stress-Adaptive Pancreatic β-Cell Mass Expansion by Coordinating Proliferation and Survival
  • Co-occurrence of Loss-of-Function GCK and ABCC8 Variants in a Pedigree With a Spectrum of Dysglycemia
  • Whey Protein Ingestion Stimulates Glucagon Secretion and Raises Blood Glucose Levels in Adults With Type 1 Diabetes
  • Islet Autotransplant Recipients Have Elevated Proinsulin–to–C-Peptide Ratios Supporting Metabolic Stress as a Cause of Islet Attrition

Recent Comments

  • A WordPress Commenter on SUCROSE: “PURE” ENERGY AT A PRICE

Archives

  • June 2026
  • May 2026
  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • November 2024
  • October 2024
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • May 2017

Categories

  • Celebrity Health
  • Diabetes
  • Food Choices
  • Fructose
  • General Sugar
  • Glucose
  • Health News
  • Insulin
  • Mental Health
  • Natural Unrefined Sugar
  • Stop Eating Sugar
  • Stop Killing Yourself
  • Sucrose
  • Sugar Science

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org
  • Home
  • Diabetes
  • Health News
  • General Sugar
  • Food Choices
  • Insulin
  • Mental Health
  • Stop Eating Sugar
  • Stop Killing Yourself
  • Fructose
  • Sugar Science

© 2026 Sugar is a DRUG | Sugar Addiction Awareness